Te Pātaka Whaioranga - Pharmac has announced the funding of risdiplam (branded as Evrysdi) for people with the rare genetic disorder spinal muscular atrophy, who meet eligibility criteria from 1 May 2023
Te Pātaka Whaioranga - Pharmac has initiated a consultation today on widening funded access to rituximab (branded as Riximyo) for people with IgG4-related disease, a chronic inflammatory condition
Specialist GP Nikki Vadgama provides some tips to make your next paediatric eczema consult easier. She includes a review of new guidelines, resources, websites and medications for paediatric eczema management